以氟脲苷为主的肝动脉灌注联合静脉化疗预防大肠癌术后肝转移的临床研究.pdfVIP

·256· 世界肿瘤砻考 2007年 第6卷 第4期 Tumour Journal oftheWorldVolume 6，Number4，Dec 2007 文章编号：1683—0342(2007)04—0256—03 术论 著 术 以氟脲苷为主的肝动脉灌注联合静脉化疗预防大肠 癌术后肝转移的临床研究 吴庆宇，倪克梁，陈珂珂，高 龙 摘要：目的 观察以氟脲苷为主的肝动脉灌注联合静脉化疗预防大肠癌术后肝转移癌的疗效及毒副反 应。方法 治疗组28例大肠癌病人，术后3wk行以氟脲苷为主的肝动脉灌注联合静脉输化疗6个周期， 对照组28例则仅予以静脉化疗6个周期，所有病例术前、术后、化疗前后均行影像学检查以评价治疗 效果，随访44mo，评价肝转移及毒副反应。结果 治疗组肝转移率为：7．1％(2／28)，对照组为：26％ (7／28)，但经统计学处理P0．05，两组之间无显著性差异，两组均无发生因化疗引起的造血系统、肝、 肾功能的损害 无化疗相关的死亡病人。结论 采用以氟脲苷为主的肝动脉灌注联合静脉化疗时可有 效减少大肠癌术后的肝转移的发生，安全有效。 关键词：肝转移癌；肝动脉灌注疗法；氟脲苷；羟基喜树碱；顺铂 中图分类号：R735．3 4 文献标识码：A Clinical research of HA1 with FUDR combined with intravenous chemotherapy in prophylaerie treatment of liver metastasis on patients with colorectal cancer WU Qing-yu, NI Ke—liang，CHEN Ke—ke，GAO Long(Shanghai Zhabei district Shibei hospital,Shanghai，200443，ChinaJ Abstract：0bjective To evaluate the efficacy and toxicity of HA1 with FUDR combined with intravenous chemotherapy in prophylactic treatment of liver metastasis on patients with colorectal cancer．Methods 28 post—operative colorectal cancer patients received HA1 with FUDR combined with intravenous chemotherapy each 3wks for 6 cycles．Other 28 patients received intravenous chemotherapy only as contro1．All patients were follow—up for 44mo，and all clinical files were documented．Results Rate of liver metastasis was 7．1％ (2／28)and 26％(7／28)in experimental group and control group，respectively(P0．05)．No severe toxicity of bone marrow,liver and kidney was documented．and mortality was 0％．Conclusions HA1 with FUDR combined with intravenous chemotherapy was effective and safe in prophylactic treatment of liver metastasis on patients with colorectal cancer． Key words：liver metastatic cancer；HAI；FUDR；hydroxycamptothecin；CDDP 肝脏是大肠癌最常见的转移器官，晚期大肠癌 发生，才是积极主动提高疗效的关键，为探索预防 有60％ 70％发生肝转移…，且多数病人的肝脏转移 大肠癌术后肝转移的有效方法，我们自2002年 8 为多发性与弥散性，因此肝转移一旦确立，无论是